MarketPulse

healthcare stocks

11 articles
The Motley FoolThe Motley Fool··David Jagielski, Cpa

AbbVie Stock Trades at Bargain Valuation as New Drugs Offset Humira Decline

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.
ABBVXLVdividend yieldhealthcare stocks
The Motley FoolThe Motley Fool··Adria Cimino

Pharma Giant and Healthcare Insurer Offer Entry Points for Long-Term Investors

Pfizer and UnitedHealth Group present buying opportunities for $500 investors. Pfizer trades at 9x forward earnings with oncology growth plans; UnitedHealth at 15x after cost-cutting initiatives.
PFEUNHlong-term investingUnitedHealth Group
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CVS and AbbVie Emerge as Healthcare Recovery Plays Amid Market Downturn

CVS and AbbVie emerge as recovery opportunities post-market pullback, leveraging diversified operations and immunology momentum respectively, with strong dividend backing investor confidence.
ABBVCVSdividend stockshealthcare stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Sub-$50 Healthcare Stocks Poised for Growth in Pharma, Oncology Sectors

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.
PFENVOEXELvaluationbiotech
The Motley FoolThe Motley Fool··Thomas Niel

Three Buffett Portfolio Stocks Poised for Growth After Leadership Transition

Three Berkshire Hathaway stocks—Chevron, Domino's Pizza, and DaVita—offer compelling long-term value with operational improvements and favorable market dynamics.
BRK.ABRK.BCVXDPZDVAenergy sectordividend stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Dividend Kings $JNJ and $ABBV Emerge as Forever Holdings for Patient Investors

Dividend Kings Johnson & Johnson and AbbVie offer 50+ years of consecutive dividend growth with resilient pipelines successfully offsetting patent expirations.
JNJABBVABTpharmaceuticalsdividend stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer and Novo Nordisk: Undervalued Pharma Giants Poised for Rebounds

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.
PFELLYNVOclinical trialshealthcare stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Healthcare Sector Poised for Growth as CVS and Vertex Eye Strategic Milestones

CVS and Vertex poised for growth through 2026 via operational improvements and expanded product pipelines. Both companies expected to deliver significant shareholder value.
CVSVRTXbiotechhealthcare stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

DexCom Positioned as Hidden Beneficiary in GLP-1 Drug Expansion

DexCom benefits from GLP-1 drug expansion as CGM devices are increasingly prescribed together, unlocking significant untapped patient markets and complementary revenue opportunities.
DXCMhealthcare stocksmedical devices
The Motley FoolThe Motley Fool··Adria Cimino

Intuitive Surgical's Market Resilience Rooted in Surgical Automation Dominance

Intuitive Surgical dominates robotic surgery market with resilient recurring revenue from instruments and services, insulating it from economic downturns.
ISRGhealthcare stockscompetitive moat
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

HCA Healthcare Posts Strong Quarter Amid Mixed 2026 Outlook

HCA Healthcare reported strong Q4 2025 results with 6.7% revenue growth, but guided for slower 3.5% growth in 2026 due to ACA credit expiration and regulatory uncertainty.
HCAearnings growthhealthcare stocks